Literature DB >> 1172813

Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose.

G P Rodnan, J A Robin, S F Tolchin, G B Elion.   

Abstract

The effect of daily administration of a single 300-mg tablet of allopurinol on serum urate levels was compared with the effect of divided doses of the drug (100 mg three times a day) in an open-labeled crossover trial of 20 patients with hyperuricemia and gout. Under both regimens of treatment there was a prompt fall in serum urate levels, and analysis of variance indicated no significant difference between the two modes of administration of allopurinol. Nor was there any significant difference in the minimum serum levels of oxypurinol. On the basis of this short-term study, the use of a single 300-mg tablet of allopurinol per day appears to be an effective means of lowering the elevated serum urate levels of individuals with gouty hyperuricemia and compares favorably with the results obtained by allopurinol in divided doses.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1172813

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  13 in total

Review 1.  Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?

Authors:  Ted R Mikuls; Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

2.  Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.

Authors:  Garry G Graham; Diluk R W Kannangara; Sophie L Stocker; Ian Portek; Kevin D Pile; Praveen L Indraratna; Indira Datta; Kenneth M Williams; Richard O Day
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

3.  Evaluation of once a day allopurinol administration in man.

Authors:  W J Currie; P Turmer; J H Young
Journal:  Br J Clin Pharmacol       Date:  1978-01       Impact factor: 4.335

4.  Efficacy of allopurinol in single daily dose.

Authors:  D Fraser; A H Little; W R Bartle
Journal:  Can Fam Physician       Date:  1977-01       Impact factor: 3.275

5.  Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite?

Authors:  I Walter-Sack; J X de Vries; C Kreiner; A Ittensohn; G Stenzhorn; A Voss; E Weber
Journal:  Clin Investig       Date:  1993-03

6.  Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.

Authors:  B Breithaupt; M Tittel
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 7.  Risks and benefits of drugs used in the management and prevention of gout.

Authors:  P G Conaghan; R O Day
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

8.  Kidney stones.

Authors:  C R Kleeman; J W Coburn; A S Brickman; D B Lee; R G Narins; R M Ehrlich
Journal:  West J Med       Date:  1980-04

9.  Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Authors:  Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 10.  Allopurinol for chronic gout.

Authors:  Rakhi Seth; Alison S R Kydd; Rachelle Buchbinder; Claire Bombardier; Christopher J Edwards
Journal:  Cochrane Database Syst Rev       Date:  2014-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.